Table 3

Association between CYP2A6 polymorphism and risk for lung cancer cell types

Smcca (n = 44)OR (95% CI)bSqcc (n = 105)OR (95% CI)Smcc + Sqcc (n = 149)OR (95% CI)Adenocarcinoma (n = 193)OR (95% CI)Control (n = 380)
Genotype
*1A/*1A10 (22.7%)1.0022 (21.0%)1.0032 (21.5%)1.0042 (21.8%)1.0054 (14.2%)
*1A/*1B16 (36.4%)0.70 (0.28–1.75)42 (40.0%)0.87 (0.46–1.66)58 (38.9%)0.79 (0.45–1.41)61 (31.6%)0.63 (0.38–1.05)123 (32.4%)
*1B/*1B8 (18.2%)0.56 (0.20–1.59)17 (16.2%)0.60 (0.29–1.27)25 (16.8%)0.59 (0.31–1.15)30 (15.5%)0.49 (0.26–0.90)c67 (17.6%)
*1A/*45 (11.4%)0.59 (0.18–1.91)10 (9.5%)0.44 (0.18–1.09)15 (10.0%)0.49 (0.23–1.05)23 (11.9%)0.58 (0.30–1.10)51 (13.4%)
*1B/*45 (11.4%)0.42 (0.13–1.35)14 (13.3%)0.48 (0.21–1.07)19 (12.8%)0.47 (0.23–0.95)c32 (16.6%)0.63 (0.35–1.13)66 (17.4%)
*4/*40 (0.0%)NC0 (0.0%)NC0 (0.0%)NC5 (2.6%)0.37 (0.12–1.11)19 (5.0%)
Allele
CYP2A6*1A41 (46.6%)1.0096 (45.7%)1.00137 (46.0%)1.00168 (43.5%)1.00282 (37.1%)
CYP2A6*1B37 (42.0%)0.79 (0.49–1.26)90 (42.9%)0.82 (0.59–1.14)127 (42.6%)0.81 (0.61–1.08)153 (39.6%)0.80 (0.61–1.04)323 (42.5%)
CYP2A6*410 (11.4%)0.51 (0.25–1.04)24 (11.4%)0.52 (0.32–0.85)c34 (11.4%)0.51 (0.34–0.79)c60 (15.5%)0.74 (0.52–1.06)136 (17.9%)
  • a Smcc, small cell carcinoma; NC, not calculated; Sqcc, Squamous cell carcinoma; *1A, CYP2A6*1A; *1B, CYP2A6*1B; *4, CYP2A6*4.

  • b OR for genotype was calculated by logistic regression analysis considering the variation of age and smoking amount.

  • c Significant decrease in OR is indicated by 95% CI. Non-small and non-squamous cell carcinomas (n = 221) were divided into adenocarcinoma (n = 193) and others.